United Imaging posts 19.43% revenue growth as R&D tops RMB 10.5bn
The Shanghai medical imaging maker reported overseas revenue up 50.30% to RMB 3.00 billion and cumulative R&D spending…
Health
Health technology, medicine and wellbeing. Asia Tech Times covers diagnostics, digital health, medtech and the science behind them in Asia's hospitals and labs.
63 stories Page 1 of 6
Ascletis ASC30 cuts HbA1c by 1.7% at 12 weeks in Phase II
Ascletis reports placebo-adjusted HbA1c reductions of 1.6% to 1.7% at 12 weeks from a U.S. Phase II study of its oral…
Taipei forum to bring 43 digital-health speakers from 11 markets
The 2026 Global Health and Welfare Forum will examine AI governance, interoperable health data and precision medicine…
Ozelle to show O-Cyte 1 analyzer at MEDICA 2026
The automated hematology analyzer pairs CBC testing with cell images that laboratory staff can review, and a six-unit…
Henlius reports 12.4-month median OS in U.S. ES-SCLC trial
The ASTRIDE study in 201 patients found median overall survival of 12.4 months with serplulimab plus chemotherapy…
Kelun-Biotech reports Phase III results for sac-TMT in first-line NSCLC
Kelun-Biotech said its TROP2 antibody-drug conjugate combined with pembrolizumab met the primary endpoint of…
Innovent presents Phase 1 data for IBI3001 at ESMO 2026
The company reported a 30.2% overall response rate among 53 efficacy-evaluable patients and said the bispecific…
Innovent reports 95% confirmed response rate for IBI354 in first-line breast cancer
Phase 2 data presented at ESMO 2026 for IBI354 plus pertuzumab in HER2-positive advanced breast cancer showed a 100%…
Wenda Pharma reports Phase II data for oral BET inhibitor in NUT carcinoma
Zhejiang Wenda Pharmaceutical Technology will publish Phase II results for NHWD-870 HCl in Chinese patients with…
Bio-Thera reports 61.2% response rate for BAT8008 with BAT1308 in first-line NSCLC
Bio-Thera Solutions presented Phase 2 data at ESMO 2026 for its TROP2-targeted antibody-drug conjugate combined with an…
Lunit and Summit Therapeutics to test AI pathology in ivonescimab research
A research agreement will apply Lunit SCOPE IO to H&E whole-slide images to study tumor microenvironment features in…
Full-Life reports Phase 1 PSA declines for FL-020 in mCRPC
Full-Life Technologies presented preliminary dose-escalation data for its PSMA-targeted alpha radiopharmaceutical at…